The next big Alzheimer’s disease study readout is almost here.
Roche is nearing the completion of a pair of clinical trials involving its experimental treatment called gantenerumab. The Swiss pharma giant will announce results from the studies within the next six weeks.
Create a display name to comment
This name will appear with your comment
